Institut Català de la Salut
[Filimontseva A, Fu Y, Halliday GM] Brain and Mind Centre & Faculty of Medicine and Health School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia. Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, MD, USA. [Vila M] Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, MD, USA. Grup de Recerca de Malalties Neurodegeneratives, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain. Department of Biochemistry and Molecular Biology, Institute of Neuroscience, Autonomous University of Barcelona, Bellaterra, Spain. Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-07-07T06:55:03Z
2025-07-07T06:55:03Z
2025-06
Aging; Neurodegeneration; Substantia nigra
Envelliment; Neurodegeneració; Substància negra
Envejecimiento; Neurodegeneración; Sustancia negra
Neuromelanin is a unique pigment made by some human catecholamine neurons. These neurons survive with their neuromelanin content for a lifetime but can also be affected by age-related neurodegenerative conditions, as observed using new neuromelanin imaging techniques. The limited quantities of neuromelanin has made understanding its normal biology difficult, but recent rodent and primate models, as well as omics studies, have confirmed its importance for selective neuronal loss in Parkinson’s disease (PD). We review the development of neuromelanin in dopamine versus noradrenaline neurons and focus on previously overlooked cellular organelles in neuromelanin formation and function. We discuss the role of neuromelanin in stimulating endogenous α-synuclein misfolding in PD which renders neuromelanin granules vulnerable, and can exacerbates other pathogenic processes.
This work was supported in part by Aligning Science Across Parkinson’s [020505] through the Michael J. Fox Foundation for Parkinson’s Research (MJFF) and also by funding to GH from the National Health and Medical Research Council of Australia [Investigator Grant 1176607]. For open access, the authors have applied a CC BY public copyright license to all Author Accepted Manuscripts arising from this submission. We would like to thank Heidi Cartwright for assistance with the figures.
Article
Versió publicada
Anglès
Parkinson, Malaltia de; Neurones dopaminèrgiques; DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Basal Ganglia Diseases::Parkinsonian Disorders::Parkinson Disease; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Amino Acids::Amino Acids, Cyclic::Amino Acids, Aromatic::Tyrosine::Melanins; ANATOMY::Nervous System::Neurons::Dopaminergic Neurons; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Nerve Tissue Proteins::Synucleins::alpha-Synuclein; ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::enfermedades de los ganglios basales::trastornos parkinsonianos::enfermedad de Parkinson; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::aminoácidos::aminoácidos cíclicos::aminoácidos aromáticos::tirosina::melaninas; ANATOMÍA::sistema nervioso::neuronas::neuronas dopaminérgicas; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas del tejido nervioso::sinucleínas::alfa-sinucleína
Elsevier
Trends in Neurosciences;48(6)
https://doi.org/10.1016/j.tins.2025.04.005
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1655]